What Are Peptides? How They Differ From Proteins, Hormones, and Small Molecules in Structure, Size, and Function

Understanding what peptides are, and how they relate to but differ from proteins, hormones, and small molecules, is foundational to interpreting the growing body of peptide research. This guide from the Peptide Register provides a clear, evidence-based overview of the structural, functional, and regulatory distinctions.

What Defines a Peptide?

Peptides are short chains of amino acids linked by peptide bonds. The conventional boundary used in biochemistry defines peptides as chains containing between 2 and approximately 50 amino acids. Chains longer than roughly 50 amino acids are generally classified as proteins, though this boundary is a convention rather than a strict rule. A dipeptide contains two amino acids, a tripeptide contains three, and an oligopeptide typically refers to chains of up to about 20 residues.

Peptides are synthesised biologically through ribosomal translation of mRNA, through enzymatic cleavage of larger precursor proteins, or through non-ribosomal pathways in microorganisms. They can also be produced synthetically via solid-phase peptide synthesis (SPPS), a method developed by Robert Bruce Merrifield in the 1960s that earned him the 1984 Nobel Prize in Chemistry.

The relatively small size of peptides gives them distinct pharmacological properties. Peptides generally have molecular weights below approximately 5,000 daltons, whereas most proteins exceed 10,000 daltons. This size difference has direct implications for stability, bioavailability, and how these molecules interact with biological targets. For a deeper look at how delivery method affects peptide absorption, see the Peptide Register's overview of peptide bioavailability across delivery routes.

How Peptides Differ From Proteins

The distinction between peptides and proteins is primarily one of size, structural complexity, and folding behaviour. Proteins are polypeptide chains, typically exceeding 50 amino acids, that fold into stable three-dimensional structures essential for their function. Proteins fold into complex tertiary and quaternary structures stabilised by hydrophobic interactions, disulfide bonds, and hydrogen bonding networks. Peptides, by contrast, are generally too short to adopt stable globular folds and tend to exist as flexible, linear, or loosely structured chains in solution.

This structural flexibility is a double-edged characteristic. It can allow peptides to interact with multiple receptor conformations, but it also makes them susceptible to rapid enzymatic degradation by proteases. Most unmodified peptides have short half-lives in circulation, often measured in minutes rather than hours. Researchers have developed various strategies to extend peptide stability, including cyclisation, PEGylation, and substitution with non-natural amino acids, though each modification introduces its own pharmacological trade-offs.

Peptides, Hormones, and Signalling Molecules: Overlapping Categories

One common source of confusion is the relationship between peptides and hormones. These categories overlap rather than being mutually exclusive. Many hormones are peptides: insulin (51 amino acids), oxytocin (9 amino acids), and vasopressin (9 amino acids) are all peptide hormones. However, not all hormones are peptides. Steroid hormones such as cortisol and oestrogen are derived from cholesterol, and thyroid hormones are modified amino acids. Conversely, not all peptides function as hormones; many serve as neurotransmitters, antimicrobial agents, or structural components.

Peptide hormones like insulin consist of 51 amino acids and act as key endocrine signalling molecules. Growth hormone-releasing hormone (GHRH), with 44 amino acids, sits near the upper boundary of the peptide classification. The Peptide Register glossary provides definitions for many of these overlapping terms.

How Peptides Differ From Small Molecules

Small molecules, as used in pharmacology, typically refer to organic compounds with molecular weights below approximately 900 daltons. Most conventional pharmaceutical drugs, such as aspirin (180 daltons) or metformin (129 daltons), fall into this category. Small molecules generally have molecular weights below 900 daltons, while peptides typically range from about 500 to 5,000 daltons.

This size difference creates meaningful pharmacological distinctions. Small molecules can usually cross cell membranes and are often orally bioavailable. Most peptides cannot passively cross lipid bilayers and are degraded by gastrointestinal enzymes, which is why many investigational peptide compounds require parenteral administration such as subcutaneous injection. Small molecules also tend to bind deep within enzyme active sites or receptor pockets, while peptides more commonly interact with larger protein-protein interaction surfaces.

Peptides occupy a pharmacological middle ground between small molecules and large biologics like monoclonal antibodies. This intermediate position gives peptides a distinct selectivity profile: they tend to have higher target specificity than small molecules but lower immunogenicity than large proteins. Over 80 peptide-based therapeutics have received regulatory approval globally as of 2024, according to published reviews, though each approved peptide has undergone its own rigorous clinical evaluation.

Why These Distinctions Matter for Research and Regulation

Understanding these categorical boundaries is not merely academic. Regulatory frameworks treat peptides, proteins, and small molecules differently. In the United States, peptide therapeutics may be regulated as drugs or as biological products depending on their characteristics. Australia's TGA classifies many peptides as Schedule 4 prescription medicines. The regulatory pathway shapes what evidence is required and how these compounds can be legally accessed. For a broader view of regulatory landscapes, the Peptide Register maintains an overview of peptide regulation across major jurisdictions.

The Peptide Register catalogues peptides by category with structured profiles covering mechanism of action, published evidence, and regulatory status. Researchers and clinicians can explore the full peptide database for detailed compound-level information. These classifications, while sometimes blurry at the boundaries, provide the necessary framework for evaluating what the published research actually demonstrates about any given compound.